# US 2026/0306665 A1 · Targeted lipid nanoparticles for treating central nervous system injuries

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306665 A1
- Document ID: US20260306665A1
- Status: Published application
- Kind: A1
- Application number: 19/641,651
- Filed: 2026-04-08
- Published: 2026-10-08
- Earliest claimed: 2025-04-08
- Assignees: Wisconsin Alumni Research Foundation
- Applicants: Wisconsin Alumni Research Foundation
- Inventors: Daniel Hellenbrand; Jacobus Burger; William Murphy; Amgad Hanna
- Web page: https://patentgrep.com/patent/US20260306665A1

## CPC

- A61K 48/0033: {the non-active part being non-polymeric}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/2013: {IL-2}
- A61K 38/2026: {IL-4}
- A61K 38/2066: {IL-10}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6911: {the form being a liposome}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides lipid nanoparticles that comprise a therapeutic agent and have an astrocyte targeting peptide linked to their surface. Suppressor RNAs that restrict transgene expression to the central nervous system or to astrocytes, in particular, are also provided. Methods of using the lipid nanoparticles and suppressor RNAs in combination of therapeutic mRNAs to treat a central nervous system injury in a subject are also provided.

## Claims

### Claim 1

A lipid nanoparticle comprising a therapeutic agent and an astrocyte targeting peptide, wherein the astrocyte targeting peptide is on the surface of the lipid nanoparticle.

### Claim 2 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle comprises an ionizable lipid, a structural lipid, a sterol, and a pegylated lipid.

### Claim 3 (depends on 2)

The lipid nanoparticle of claim 2, wherein the molar ratios of the ionizable lipid, the structural lipid, the sterol, and the pegylated lipid are 50:10:38.5:1.5.

### Claim 4 (depends on 2)

The lipid nanoparticle of claim 2, wherein:
a) the ionizable lipid is SM-102;
b) the structural lipid is 1,2-distearoyl-sn-glycero-3-PC (1,2-DSPC);
c) the sterol is cholesterol; and/or
d) the pegylated lipid is selected from a group consisting of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000], and combinations thereof.

### Claim 5 (depends on 1)

The lipid nanoparticle of claim 1, wherein the astrocyte targeting peptide is selected from a group consisting of SEQ ID NO: 1 (AS1-N), SEQ ID NO: 2 (AS1-C), SEQ ID NO: 5 (A-21-1-N), SEQ ID NO: 7 (A+C1-11-N), SEQ ID NO: 8 (A+C1-11-C), SEQ ID NO: 9 (A+C4-9-N), SEQ ID NO: 10 (A+C4-9-C), SEQ ID NO: 12 (ADC6-5-C), SEQ ID NO: 13 (AC2-6-N), and SEQ ID NO: 16 (A+C5-1-C).

### Claim 6 (depends on 1)

The lipid nanoparticle of claim 1, wherein the astrocyte targeting peptide is linked to the lipid nanoparticle surface via a pegylated lipid.

### Claim 7 (depends on 6)

The lipid nanoparticle of claim 6, wherein the astrocyte targeting peptide comprises a thiol group and the pegylated lipid comprises a maleimide group, and wherein the thiol group is linked to the maleimide group via a thiosuccinimide bond.

### Claim 8 (depends on 1)

The lipid nanoparticle of claim 1, wherein the therapeutic agent is a therapeutic mRNA that encodes IL-2, IL-4, IL-10, or IL-13.

### Claim 9 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle further comprises an anti-inflammatory peptide and optionally wherein the anti-inflammatory peptide comprises a thiol group and the pegylated lipid comprises a maleimide group, and wherein the thiol group is linked to the maleimide group via a thiosuccinimide bond.

### Claim 10 (depends on 9)

The lipid nanoparticle of claim 9, wherein the molar ratio of anti-inflammatory peptide to the astrocyte targeting peptide is between 0.1:1 and 1:1.

### Claim 11

A suppressor mRNA comprising a nucleotide sequence encoding a repressor protein and comprises at least one copy of an astrocyte-expressed miRNA target site in a 5′ untranslated region (UTR) and/or a 3′ UTR of the suppressor mRNA.

### Claim 12 (depends on 11)

The suppressor mRNA of claim 11, wherein the at least one copy of the astrocyte-expressed miRNA target site comprises at least one copy of a first astrocyte-expressed miRNA target site and at least one copy of a second astrocyte-expressed miRNA target site.

### Claim 13 (depends on 12)

The suppressor mRNA of claim 12, wherein:
a) the first astrocyte-expressed miRNA target site is complementary to miR-449a and the second astrocyte-expressed miRNA target site is complementary to miR-143; or
b) the first astrocyte-expressed miRNA target site is complementary to miR-410 and the second astrocyte-expressed miRNA target site is complementary to miR-135a.

### Claim 14 (depends on 13)

The suppressor mRNA of claim 13, wherein the suppressor mRNA comprises SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20.

### Claim 15 (depends on 11)

A composition comprising the suppressor mRNA of claim 11 and a therapeutic mRNA, wherein the therapeutic mRNA comprises a repressor binding domain in the 5′ UTR and a nucleotide sequence encoding a therapeutic or reporter protein.

### Claim 16 (depends on 15)

A lipid nanoparticle comprising the composition of claim 15.

### Claim 17

A method of treating a central nervous system (CNS) injury in a subject, the method comprising: administering a lipid nanoparticle comprising a therapeutic agent or therapeutic protein to the subject, wherein the lipid nanoparticle is delivered to the CNS injury.

### Claim 18 (depends on 17)

The method of claim 17, wherein the lipid nanoparticle comprises a suppressor mRNA and a therapeutic mRNA, wherein the suppressor mRNA comprises a nucleotide sequence encoding a repressor protein and comprises at least one copy of an astrocyte-expressed miRNA target site in a 5′ untranslated region (UTR) and/or a 3′ UTR of the suppressor mRNA and wherein the therapeutic mRNA comprises a repressor binding domain in the 5′ UTR and a nucleotide sequence encoding a therapeutic or reporter protein.

### Claim 19 (depends on 17)

The method of claim 17, wherein the lipid nanoparticle is administered to the subject intravenously.

### Claim 20 (depends on 17)

The method of claim 17, wherein the lipid nanoparticle is administered within 8 hours of the CNS injury.

### Claim 21 (depends on 17)

The method of claim 17, wherein the CNS injury is a spinal cord injury, a traumatic brain injury, or a hemorrhagic stroke.
